News

This week, GigaGen has launched a Phase 1 trial for GIGA-2339, a potential functional cure for chronic Hepatitis B, public health concerns like the California raw milk recall due to H5N1 and new findings linking lung dysfunction to cognitive decline in Long COVID patients, and more.

This study explores HLA-E as a target to activate the immune system in HBV infection, identifying a stable peptide, Env371-379 L6I, that effectively triggers T-cell responses.

With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.

Mild reactions were experienced in 46% of recipients.

New research using advanced MRI techniques explores how impaired pulmonary gas exchange may contribute to cognitive impairments in Long COVID patients, offering insights for potential treatment strategies.

Recent data shows a 1 in 5 risk of unvaccinated house members transmitting the respiratory virus to other nonimmunized members.

CDPH advises consuming pasteurized milk, which kills the virus, while the state increases testing and monitoring following 29 confirmed human cases of H5N1 linked to infected dairy cows.

It is not only about cooking the food to the correct temperature, but also how long the food should sit out, and safe storage after the meal is over. Here is more information to have a healthy holiday.

Using fecal microbiota transplantation within the CGA framework further enhanced survival and care efficiency.

Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for the concerns around infective endocarditis and when choosing empiric therapy.

Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

Recent studies show oral vancomycin reduces CDI by 64% in stem cell transplant patients, Biktarvy is effective for HIV/HBV co-infection, climate change drives rising dengue cases, and a 7-day antibiotic regimen is as effective as 14 days for bloodstream infections.

Kenneth Lawrence, PharmD, discusses the global problem and the need for a layered, multifaceted approach to antimicrobial resistance (AMR) and some of the ongoing inroads and progress being made to address the medical issue.

Robert H. Hopkins, Jr., MD, medical director, National Foundation for Infectious Diseases (NFID) and ACIP liaison, offers guidance and insights on a variety of respiratory vaccines.

Wolverine Packing Co is recalling ground beef due to potential contamination with E coli O157:H7

Along with the CDC, we highlight the One Health approach and advocate for effective infection control measures, such as vaccination and innovative technologies, to prevent the spread of resistant pathogens and combat AMR.

The country’s program yielded screening and treatment in almost two thirds of the identified at-risk population.

Nicole M Iovine discusses the risks associated with this particular E coli strain, challenges posed by organic farming, and offers practical food safety tips to protect vulnerable populations.

Here is a recap of the latest happenings during C diff awareness month.

The BALANCE trial suggests that shorter treatment durations may reduce healthcare costs, antibiotic exposure, and antimicrobial resistance risk, providing an alternative for critically ill patients.

The person had recently traveled to areas experiencing clade I mpox virus transmission and sought medical care for mpox symptoms in the United States.

A new study confirms the growing belief and evidence this vector-borne diseases will increase and see a greater burden globally.

California reports a suspected case of a child; Oregon's first human case linked to a poultry outbreak; and Canada's first locally acquired case in a critically ill teen.

The ALLIANCE Phase III study demonstrated that Biktarvy, a TAF-based regimen, achieved sustained virologic suppression in adults with HIV/HBV co-infection.

Atea Pharmaceuticals has been reporting data on its combination of bemnifosbuvir and ruzasvir as a potential treatment for the virus.

In recognition of C difficile Awareness Month this November, the CDC's 2023 HAI Progress Report highlights continued progress in reducing CDIs across US healthcare settings.